Ferring Pharmaceuticals

Press Release

Northville Resident Wins Runner-Up Prize in Ferring’s My Little Miracle Essay Contest

Pictured: Evan (l) and Tyler (r), 11-month-old sons of John Doskocz, runner-up winner of Ferring Pharmaceutical’s My Little Miracle Essay Contest. John’s $5,000 prize will be placed in 529 education funds for Evan’s and Tyler’s future education.

Northville, MI – December 9, 2004 – John Doskocz, Northville resident, received a $5,000 runner-up prize from Ferring Pharmaceuticals for his entry in the Company’s My Little Miracle Essay Contest. John’s entry, How We Got to Our Dream Destination, chronicled the long path to his sons’ births. The prize money will be deposited into education funds for Evan and Tyler, his 11-month-old sons born with the help of
Bravelle™ (urofollitropin for injection, purified) and Repronex™ (menotropins for injection, USP) – two of Ferring’s fertility treatments.

“We thought that one double miracle this year was amazing with the birth of our twin boys Tyler and Evan. Now Ferring has not only contributed to their birth but also to their future,” said John Doskocz. “Our new family sincerely thanks you for another wonderful surprise in 2004.”

“We are delighted to offer this program to help fertility patients contribute to their children’s future,” said Wayne Anderson, president, Ferring Pharmaceuticals. “Ferring is committed to providing patients with safe, effective and affordable fertility treatments. This program is an extension of Ferring’s support of its patients.”

The My Little Miracle Essay Contest celebrated the births of children made possible through Ferring’s fertility treatments, Bravelle™ (urofollitropin for injection, purified) and Repronex™ (menotropins for injection, USP). Ferring awarded $25,000 in education funds to 12 winners from around the country.

About the Doskoczs

After trying unsuccessfully to become pregnant for three years, the Doskoczs decided to seek treatment at the Colorado Center for Reproductive Medicine. The couple met with William B. Schoolcraft, M.D., who helped them through their fertility treatments. In his essay, John speaks of their experience:

Being unable to conceive for a long time is like being at an airport and being unable to get on any flight while those around you seem to be hopping on planes left and right to their dream destination. They want to tell you about their wonderful experience when they return and naturally are pulling out many photos of their trip to share with you. All the while they have no idea this is rubbing salt into your wound. With modern medicine, we [were] told that we could possibly conceive … So now we’re stuck at the airport, but are instructed we can maybe make our destination if we row a boat. It will take longer and require much more work, and there’s no guarantee [that] the boat won’t sink along the way. With really no other option … we grab our oars! … You have to have faith in yourself and faith in the products and process that the doctor has directed. … you don’t realize how many others have had to take the boat until you are out there rowing yourself. It’s good to know you’re not alone. … Well, our boat was as strong as our determination, and with the help of Bravelle™ and Repronex™, we have Tyler and Evan, our beautiful twin boys!!

About Bravelle™ and Repronex™

Bravelle™, a highly purified human-derived follicle-stimulating hormone (hFSH) for infertility treatment, contains 75 IU of FSH and up to two percent LH activity.

Bravelle™, administered SC or IM in conjunction with hCG, is indicated for ovulation induction following pituitary suppression.

Bravelle™, administered SC in conjunction with hCG, is also indicated for multiple follicular development during ART cycles in patients who have previously received pituitary suppression. Repronex™ is the only human menopausal gonadotropin (hMG) on the market in the U.S. and is approved for both subcutaneous and intramuscular administration.

Bravelle™ (urofollitropin for injection, purified) and Repronex™ (menotropins for injections, USP), like all gonadotropins, are potent substances capable of causing mild to severe adverse reactions, including OHSS (incidence of 6.0% and 3.5%, respectively), with or without pulmonary or vascular complications, in women undergoing therapy for infertility.

Both treatments are marketed by Ferring Pharmaceuticals Inc., a world leader in naturally occurring protein hormones. Only physicians thoroughly familiar with infertility treatment, including the risk of multiple births and adverse reactions, should prescribe these medications. Like other products for ovarian stimulation, treatment with
Repronex™ and/ or Bravelle™ may result in multiple gestations.

About Ferring Pharmaceuticals

Ferring Pharmaceuticals, part of the Ferring Group, a privately owned, international pharmaceutical company, markets Bravelle™, Repronex™ and Novarel™ (chorionic gonadotropin for injection, USP) in the U.S. to infertility specialists and their patients. The Ferring Group specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, gastroenterology, obstetrics/gynecology and infertility. For more information, call 888-337-7464 or visit www.ferringusa.com or www.ferringfertility.com.

# # #

For full prescribing information for Bravelle™ and/ or Repronex™, please contact Kelly Laban.